低用量タリドミドとコルキシンで治療された耐火性口腔潰瘍の成功リミッション:ケース報告
Shun-Yu Kan1, Yu-Kai Sung2, Chia-Lu Hsu3
1School of Dentistry, National Defense Medical University, Number 161, Section 6, Minquan East Road, Neihu District, Taipei City 114, Taiwan.
Reports (MDPI)
|February 20, 2026
まとめ
標準治療に耐性のある不治性口腔潰瘍は,低用量タリドミドとコルキシンによる併用療法から利益を得ることができます. このアプローチは,従来の口腔潰瘍管理に反応しない患者の持続的な寛解をもたらしました.
科学分野:
- 歯科 歯科は,歯科を専門とする歯科です.
- 口腔医学は,口腔医学というものです.
- 薬理学 薬理学とは
背景:
- 口腔潰瘍は一般的であり,標準的な治療はエチオロギーの除去と薬物療法,しばしば局所用コルチコステロイドを含む.
- 耐火性口腔潰瘍は,患者の生活の質に大きな影響を与え,全身的な評価を必要とします.
- コルチコステロイドやエチオロジックファクター除去を含む従来の治療法は,このケースでは効果的ではなかった.
研究 の 目的:
- 複数の従来の治療に耐性のある耐火性口腔潰瘍の症例を提示するために.
- 口腔潰瘍症例に挑戦するための代替治療戦略を探求する.
主な方法:
- 耐火性口腔潰瘍の患者が,パーキンソン病に関連する外傷源に対処するために,歯科介入 (歯の丸め,閉塞性噛み付いたプレート) を受けました.
- 潰瘍病変の生検が行われました.
- 治療には,従来の治療法 (コルチコステロイド) と病因因子の除去が含まれており,どれも無効であることが判明しました.
主要な成果:
- 低用量タリドミド (50 mg/日) とコルキシン (1.5 mg/日) の併用療法が開始されました.
- 患者は実質的な臨床改善と完全な寛解を達成しました.
- 寛解は再発することなく6ヶ月以上持続しました.
結論:
- 低用量タリドミドとコルキシンによる併用治療は,従来の治療に反応しない耐性口腔潰瘍の治療に有望であることが示されています.
- この治療的アプローチは,より大きな研究で有効性と安全性のさらなる調査を正当化しています.
- この発見は仮説を生み出すものであり,難しい口腔潰瘍症例の新たな治療法の可能性を示唆している.
関連する概念動画
Drugs for Treatment of Ulcerative Colitis in IBD
553
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
553
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
547
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
547
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
583
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
583
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
1.7K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.7K
Peptic Ulcer Disease IV: Management
553
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
553
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
1.5K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
1.5K

